



CHOATE HALL & STEWART LLP

RECEIVED
CENTRAL FAX CENTER

FEB 28 2007

Fax

Recipient	Company	Fax	Phone
Examiner Rogers	USPTO	571-273-8300	571-272-7838

From	Mary Harrington for Charles E. Lyon, D.Phil.	Number of Pages	8 (including this page)
------	---	-----------------	-------------------------

Date	February 28, 2007	Client Number	0492611-0505
------	-------------------	---------------	--------------

Phone	617-248-4793	Operator	Time Sent
-------	--------------	----------	-----------

Comments	Applicant:	Chau <i>et al.</i>	Examiner:	Rogers, J.W.
	Serial No.:	10/668,045	Art Unit:	1618
	Filed:	September 22, 2003		
	For:	POLYMER-LINKER-DRUG CONJUGATES FOR TARGETED DRUG DELIVERY		

Dear Examiner Rogers

Per our telephone conference of February 27, 2007, please find the following:

- (1) Re-Submission of Originally Filed Appendix A (2 pp);
- (2) Appendix A (4 pp); and
- (3) Stamped return receipt postcard (1 pg) itemizing Appendix A (4 pp) as one of the documents that was included with the original filing on September 22, 2003.

Please feel free to call if you have any further questions.

With best regards,

Charles E. Lyon, D.Phil.
Reg. No. 56630

Return by Inter-office Mail Hold for pick-up

This Message is transmitted to you by the law firm of Choate, Hall & Stewart LLP. The substance of this message, along with any attachments, may be confidential and legally privileged. If you are not the designated recipient of this message, please destroy it and notify the sender of the error by return e-mail or by calling 1-800-520-2427.

Under regulations of the Treasury Department, we are required to include the following statement in this message: Any advice contained herein (or in any attachment hereto) regarding federal tax matters was not intended or written by the sender to be used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

For more information about Choate, Hall & Stewart LLP, please visit us at www.choate.com
Two International Place | Boston MA 02110 | t 617-248-5000 | f 617-248-4000 | choate.com

4180018v1

RECEIVED
CENTRAL FAX CENTER

FEB 28 2007

ATTORNEY'S DOCKET NUMBER: 0492611-0505 (MIT 9991)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEApplicant: Chau *et al.*

Serial No.: 10/668,045

Filed: September 22, 2003

For: POLYMER-LINKER-DRUG CONJUGATES FOR TARGETED DRUG
DELIVERY

Examiner: Rogers, J.W.

Art Unit: 1618

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Certificate of Facsimile Transmission
Pursuant to 1096 OG 30-31I hereby certify that this correspondence is being facsimile transmitted to the US
Patent & Trademark Office (571) 273-8300 on the date indicated below.

February 28, 2007

Date

Signature

Mary Harrington

Typed or Printed Name of person signing certificate

RE-SUBMISSION OF ORIGINALLY FILED APPENDIX A

This paper is being filed further to a conversation between the undersigned and Examiner Rogers on February 27, 2007. The Examiner had previously contacted the undersigned on October 31, 2006 to inform him that a copy of Appendix A (referred to on page 16, line 16 of the specification) could not be found in the PTO file for this case.

The undersigned confirmed that Appendix A had been included in the original filing by referring to the stamped return postcard which itemized the originally filed papers, including 4 pages for Appendix A. On October 31, 2006 the undersigned faxed Applicant's file copy of the stamped postcard and Appendix A directly to the Examiner for review. On February 27, 2007, the Examiner contacted the undersigned requesting that the undersigned send the same documents to the general PTO fax number so that they can be entered into the file.

Applicant is hereby complying with this request and respectfully requests that these papers be properly entered into the PTO file. Since Appendix A was present at the time of filing it is Applicant's understanding that a formal Amendment to the Specification is not required in order to add Appendix A to the specification. However, if Applicant is mistaken and a formal Amendment to the Specification is required then Applicant hereby requests that the Specification be amended to include Appendix A. This Amendment would add no new matter since Appendix

U.S.S.N: 10/668,045
4180008v1

Page 1 of 2


Attorney Docket No.: 0492611-0505
Client Reference No.: MIT 9991

A was present at the time of filing as evidence by the stamped return postcard and as acknowledged by the Examiner during the call held on February 27, 2007.

Please charge any additional fees associated with this filing, or apply any credits, to our Deposit Account No. 03-1721.

Respectfully Submitted,
CHOATE, HALL & STEWART LLP

Date: February 28, 2007


Charles E. Lyon, D.Phil.
Reg. No. 51,908

PATENT DEPARTMENT
CHOATE, HALL & STEWART LLP
Two International Place
Boston, Massachusetts 02110
Telephone: (617) 248-5000
Facsimile: (617) 248-4000

APPENDIX A
A PARTIAL LIST OF TUMOR-ASSOCIATED PROTEASES AND THEIR SUBSTRATE SPECIFICITY

PROTEASE	CLASS	SUBSTRATE SPECIFICITY	COMMENTS	REFERENCES
Prostate specific antigen (PSA)	Serine	HSSKLQ↓ (most selective) SS(Y/F)Y↓S(G/S) (most sensitive)	Chymotrypsin-like substrate specificity. Uniquely expressed by prostate glandular cells. Elevated level in prostate carcinoma. Secreted by PC-82 human prostate tumor model	(Denineade, Lou et al. 1997) (Coombs, Bergstrom et al. 1998)
Human kallikrein 2 (hk2)	Serine	(Q/E)(R/K/H)R↓LXY (cleavage sites in semenogelin I and II) PFR↓	Trypsin-like substrate specificity. Uniquely expressed by prostate glandular cells. Elevated level in prostate carcinoma. Activate PSA and uPA. Cleave fibronectin	(Lovgren, Airas et al. 1999)
Urokinase-type plasminogen activator (uPA)	Serine	KKSPGR↓VVGGSVAAH (sequence of plasminogen) GPR↓ GPK↓	Chymotrypsin family. Overexpressed in a number of epithelial cancers. Involved in tumor-associated fibrolysis, associated with malignancy.	(Suzumiya, Hasui et al. 1988) (de Bruin, Verspaget et al. 1989) (Rijken and Groeneveld 1991) (Ke, Coombs et al. 1997)
Fibroblast activating protein α (FAPα)	Serine	Collagenolytic activity- sequence specificity not determined Dipeptidyl peptidase - AP↓	Cell surface antigen of reactive tumor stromal fibroblasts in epithelial cancers or granulation tissue during wound healing. Degrade ECM. Normal tissues are FAP negative.	(Park, Lenter et al. 1999)

PROTEASE	CLASS	SUBSTRATE SPECIFICITY	COMMENTS	REFERENCES
Meprin α	Metallo (Zn^{++})	RPPGF \downarrow SPFR (sequence of bradykinin)	Expressed normally in intestinal and kidney epithelial cells. Secreted or forms a membrane-bound tetramer with β subunits. Elevated levels of meprin observed in colon carcinoma. Degrade ECM.	(Kohler, Kruse et al. 2000) (Wolz, Harris et al. 1991)
Meprin β	Metallo (Zn^{++})	YEE \downarrow EEI SNFD \downarrow DY WM \downarrow DF	Expressed normally in intestinal and kidney epithelial cells. Forms a membrane-bound tetramer with α subunits. Elevated levels of meprin observed in colon carcinoma. Degrade ECM.	(Chestukhin, Litovchick et al. 1997)
MT1-MMP	Metallo (Zn^{++})	PLP \downarrow L	Membrane bound enzymes involved in the activation of MMP-2. Found in a number of cancer types. Constitutively activated.	(Woessner and Nagase 2000) (Ohkubo, Miyadera et al. 1999)
Cathepsin B	Cysteine	RR \downarrow FR \downarrow	Lysosomal enzymes normally present intracellularly. Broad substrate selectivity. Secreted or membrane bound for some cancer cells (e.g., Cathepsin B in B16 melanoma and colon carcinoma; Cathepsin L in lung cancer cells). May degrade ECM.	(Corticchiato, Cajot et al. 1992) (Moin, Cao et al. 1998) (Khalfan 1991)
Cathepsin L	Cysteine	FR \downarrow		(Heidtmann, Salge et al. 1993) (Khalfan 1991)

REFERENCES

- Chestukhin, A., L. Litovchick, et al. (1997). "Unveiling the substrate specificity of meprin β on the basis of the site in protein kinase A cleaved by the kinase splitting membrane proteinase." J. Biol. Chem. **272**(6): 3153-3160.
- Corticchiato, O., J. F. Cajot, et al. (1992). "Cystatin-C and cathepsin-B in human colon-carcinoma-expression by cell-lines and matrix degradation." Int. J. Cancer **52**(4): 645-652.
- de Bruin, P. A. F., H. W. Verspaget, et al. (1989). "Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens." Br. J. Cancer **60**: 397-400.
- Denmeade, S. R., W. Lou, et al. (1997). "Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen." Cancer research **57**: 4924-4930.
- Coombs, G. S., R. C. Bergstrom, et al. (1998). "Substrate specificity of prostate-specific antigen (PSA)." Chemistry & Biology **5**(9): 475-488.
- Heidtmann, H. H., U. Salge, et al. (1993). "Secretion of a latent, acid activatable cathepsin-L precursor by human nonsmall cell lung cancer cell-lines." Oncology Res. **5**(10-11): 441-451.
- Ke, S.-H., G. S. Coombs, et al. (1997). "Distinguishing the specificities of closely related proteases." J. Biol. Chem. **272**(26): 16603-16609.
- Khalfan, H. A. (1991). "Study of thiol proteases of normal human skin fibroblasts." Cell Biochemistry and Function **9**(1): 55-62.
- Kohler, D., M. N. Kruse, et al. (2000). "Heterologously overexpressed, affinity-purified human meprin alpha is functionally active and cleaves components of the basement membrane in vitro." FEBS Letters **465**(1): 2-7.
- Lovgren, J., K. Airas, et al. (1999). "Enzymatic action of human glandular kallikrein 2 (hK2)." Eur. J. Biochem. **262**: 781-789.
- Moin, K., L. Cao, et al. (1998). "Tumor cell membrane cathepsin B." Biol. Chem. **379**(8-9): 1093-1099.
- Ohkubo, S., K. Miyadera, et al. (1999). "Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library." Biochem. Biophys. Res. Commun. **266**: 308-313.

- Park, J. E., M. C. Lenter, et al. (1999). "Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts." J. Biol. Chem. 274(51): 36505-36512.
- Rijken, D. C. and E. Groeneweld (1991). "Substrate specificity of tissue-type and urokinase-type plasminogen activators." Biochemical and biophysical research communications 174(2): 432-438.
- Suzumiya, J., Y. Hasui, et al. (1988). "Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas." Int. J. Cancer 42: 627-632.
- Wocessner, J. F. and H. Nagase (2000). Matrix metalloproteinases and TIMPS. New York, New York, Oxford University Press.
- Wolz, R. L., R. B. Harris, et al. (1991). "Mapping the active site of meprin-A with peptide substrates and inhibitors." Biochemistry 30(34): 8488-8493.


BEST AVAILABLE COPY

Filed: September 22, 2003Express Mail: EV 170393752 US*BHTRC/INH*

The Patent and Trademark Office stamping sets forth receipt date (or both the receipt date and the application number) of a Utility Patent Application identified as follows:

Applicant: Chau, et al.
For: POLYMER-LINKER-DRUG CONJUGATES FOR
TARGETED DRUG DELIVERY

1. U.S. National Patent Application comprising: 68 pages of specification (including 3 pages of claims, 1 page of abstract and 4 pages of Appendix A) and 25 sheets of drawings;
2. Patent Application Transmittal Letter (4 pages);
3. Statement of Limited Recognition Under 37 C.F.R. §10.9(b) (1 page); and
4. Return Postcard.

Attorney: CEL/izaAttorney Docket No.: 0492611-0505 (MIT 5991)

03970 U.S. PTO
10/668045
09/22/03